Torsten Pietsch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6822976/publications.pdf

Version: 2024-02-01

74 papers	4,669 citations	218677 26 h-index	118850 62 g-index
75 all docs	75 docs citations	75 times ranked	5999 citing authors

#	Article	IF	Citations
1	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	3.7	9
2	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers, 2022, 14, 126.	3.7	12
3	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3ÂK27M Mutant Diffuse Midline Glioma. Clinical Neuroradiology, 2022, 32, 249-258.	1.9	8
4	EPEN-24. Biological markers of ependymoma in children and adolescents (BIOMECA): Systematic comparison of methods for the precise evaluation of biomarkers for ependymoma diagnosis and prognostication. Neuro-Oncology, 2022, 24, i44-i44.	1.2	0
5	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
6	GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy â€“ final of the SIOP CNS GCT II study. Neuro-Oncology, 2022, 24, i56-i56.	1.2	0
7	Biology and grading of pleomorphic xanthoastrocytomaâ€”what have we learned about it?. Brain Pathology, 2021, 31, 20-32.	4.1	32
8	Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma. Child's Nervous System, 2021, 37, 809-818.	1.1	22
9	<scp>MGMT</scp> promoter methylation analysis for allocating combined <scp>CCNU</scp>/<scp>TMZ</scp> chemotherapy: Lessons learned from the <scp>CeTeG</scp>/<scp>NOA</scp>â€09 trial. International Journal of Cancer, 2021, 148, 1695-1707.	5.1	11
10	Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathologica, 2021, 141, 455-466.	7.7	37
11	Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. Familial Cancer, 2021, 20, 273-277.	1.9	9
12	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. Pharmaceuticals, 2021, 14, 195.	3.8	7
13	Chemotherapy for adult patients with spinal cord gliomas. Neuro-Oncology Practice, 2021, 8, 475-484.	1.6	1
14	Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups. Journal of Neuropathology and Experimental Neurology, 2021, 80, 419-430.	1.7	7
15	Pediatric ependymoma: an overview of a complex disease. Child's Nervous System, 2021, 37, 2451-2463.	1.1	26
16	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
17	Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404.		11
18	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. Neuro-Oncology, 2021, 23, 1148-1162.	1.2	9

#	Article	IF	Citations
19	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
20	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathologica, 2020, 139, 277-286.	7.7	36
21	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€“ A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
22	Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome. Child's Nervous System, 2020, 36, 2693-2700.	1.1	14
23	YAP1/TAZ drives ependymoma-like tumour formation in mice. Nature Communications, 2020, 11, 2380.	12.8	32
24	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica, 2020, 140, 405-407.	7.7	30
25	Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric lowâ€grade glioma patientsâ€"Report from the German <scp>SIOPâ€ŁGG</scp> 2004 cohort. International Journal of Cancer, 2020, 147, 3471-3489.	5.1	19
26	Prognostic impact of distinct genetic entities in pediatric diffuse glioma <scp>WHO</scp>â€grade <scp>II</scp>â€"Report from the German/Swiss <scp>SIOPâ€ŁGG</scp> 2004 cohort. International Journal of Cancer, 2020, 147, 2159-2175.	5.1	8
27	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
28	GCT-76. 24Gy WHOLE VENTRICULAR RADIOTHERAPY ALONE IS SUFFICIENT FOR DISEASE CONTROL IN LOCALISED GERMINOMA IN CR AFTER INITIAL CHEMOTHERAPY â€“ EARLY RESULTS OF THE SIOP CNS GCT II STUDY. Neuro-Oncology, 2020, 22, iii343-iii344.	1.2	8
29	EPEN-27. CDKN2A DELETION IN SUPRATENTORIAL EPENDYMOMA WITH RELA ALTERATION INDICATES A DISMAL PROGNOSIS â€“ A RETROSPECTIVE ANALYSIS OF THE HIT EPENDYMOMA TRIAL COHORT. Neuro-Oncology, 2020, 22, iii313-iii313.	1.2	0
30	HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN. Neuro-Oncology, 2020, 22, iii349-iii350.	1.2	0
31	PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORSâ€"THE MNP 2.0 STUDY. Neuro-Oncology, 2020, 22, iii426-iii426.	1.2	0
32	Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study. Journal of Neurosurgery: Pediatrics, 2020, 25, 425-433.	1.3	2
33	MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. Clinical Neuroradiology, 2019, 29, 595-604.	1.9	26
34	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. Journal of Neuropathology and Experimental Neurology, 2019, 78, 791-797.	1.7	50
35	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. American Journal of Neuroradiology, 2019, 40, 1811-1817.	2.4	9
36	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International Journal of Molecular Sciences, 2019, 20, 4267.	4.1	10

#	Article	IF	Citations
37	Mutated SON putatively causes a cancer syndrome comprising high-risk medulloblastoma combined with cafÃ©-au-lait spots. Familial Cancer, 2019, 18, 353-358.	1.9	4
38	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. Neuro-Oncology, 2019, 21, ii82-ii82.	1.2	2
39	EPEN-07. EPENDYMOMAS IN INFANCY: UNDERLYING GENETIC ALTERATIONS, HISTOLOGICAL FEATURES AND CLINICAL OUTCOME. Neuro-Oncology, 2019, 21, ii78-ii78.	1.2	1
40	Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. Journal of Neuro-Oncology, 2019, 142, 435-444.	2.9	14
41	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. Acta Neuropathologica, 2019, 137, 847-850.	7.7	7
42	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features â€“ a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica Communications, 2019, 7, 181.	5.2	21
43	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
44	Childhood supratentorial ependymomas with YAP1â€MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	4.1	75
45	Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region. Neuro-Oncology, 2019, 21, 137-138.	1.2	3
46	ATRT-15. SPINAL CORD ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT) IN CHILDREN: RESULTS OF A EUROPEAN RETROSPECTIVE ANALYSIS UNDER THE AUSPICES OF THE EU-RHAB STUDY GROUP. Neuro-Oncology, 2018, 20, i30-i30.	1.2	0
47	TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICSâ€”THE PROSPECTIVE MNP2.0 STUDY. Neuro-Oncology, 2018, 20, i181-i181.	1.2	0
48	MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES. Neuro-Oncology, 2018, 20, i127-i127.	1.2	0
49	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. Neuro-Oncology, 2018, 20, i144-i145.	1.2	1
50	Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. Neuro-Oncology Practice, 2017, 4, 29-39.	1.6	12
51	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology, 2017, 88, 1422-1430.	1.1	54
52	Outcome of patients with intracranial non-germinomatous germ cell tumorsâ€”lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology, 2017, 19, 1661-1672.	1.2	150
53	Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. American Journal of Neuroradiology, 2017, 38, 1892-1898.	2.4	21
54	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478

#	Article	IF	Citations
55	Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro-Oncology, 2016, 18, 919-927.	1.2	68
56	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	1.6	121
57	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanineâ€“DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of Clinical Oncology, 2016, 34, 1611-1619.	1.6	151
58	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro-Oncology, 2016, 18, 790-796.	1.2	67
59	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
60	MB-28 * GENOME-WIDE COPY NUMBER ANALYSIS, NEUROPATHOLOGICAL CLASSIFICATION AND ANALYSIS OF HEDGEHOG ACTIVATION: HISTOLOGY REFLECTS GENETICS AND BIOLOGY IN MEDULLOBLASTOMAS OF YOUNG CHILDREN. Neuro-Oncology, 2015, 17, iii26-iii26.	1.2	0
61	OT-10 * IMPLEMENTATION OF NEXT GENERATION COPY NUMBER AND MUTATIONAL ANALYSIS IN ROUTINE NEUROPATHOLOGY: MOLECULAR INVERSION PROFILING IS A HELPFUL TOOL IN DIFFERENTIAL DIAGNOSTICS AND PROGNOSTIFICATION OF PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2015, 17, iii30-iii31.	1.2	1
62	Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. Neuro-Oncology, 2015, 17, 1157-1165.	1.2	33
63	High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors. Journal of Neuropathology and Experimental Neurology, 2015, 74, 110-120.	1.7	31
64	Absence of <scp>TERT</scp> promoter mutations in primary melanocytic tumours of the central nervous system. Neuropathology and Applied Neurobiology, 2014, 40, 794-797.	3.2	19
65	Supratentorial ependymomas of childhood carry C11orf95â€“RELA fusions leading to pathological activation of the NF-ÎºB signaling pathway. Acta Neuropathologica, 2014, 127, 609-611.	7.7	103
66	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 2014, 135, 1822-1831.	5.1	117
67	H3F3A K27M Mutation in Pediatric CNS Tumors. American Journal of Clinical Pathology, 2013, 139, 345-349.	0.7	116
68	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 2012, 30, 3187-3193.	1.6	270
69	Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. PLoS ONE, 2008, 3, e3088.	2.5	606
70	Expression of the Neurotrophin Receptor p75^{NTR}in Medulloblastomas Is Correlated with Distinct Histological and Clinical Features: Evidence for a Medulloblastoma Subtype Derived from the External Granule Cell Layer. Journal of Neuropathology and Experimental Neurology, 2000, 59, 229-240.	1.7	83
71	Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. Journal of Neuro-Oncology, 1999, 44, 23-33.	2.9	44
72	Vascular endothelial growth factor (VEGF) in astrocytic gliomas–a prognostic factor?. Journal of Neuro-Oncology, 1999, 45, 117-125.	2.9	53

#	Article	IF	Citations
73	Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. Journal of Cancer Research and Clinical Oncology, 1996, 122, 301-306.	2.5	98
74	Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas. Oncotarget, 0, 7, 41898-41912.	1.8	7